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Abstract
Patients with psoriatic arthritis (PsA) may not be optimally treated. The impact of the disease extends beyond skin and
joint symptoms, impairing quality of life. This indicates that the adoption of a patient-focused approach to PsA manage-
ment is necessary. An expert multidisciplinary working group was convened, with the objective of developing an
informed perspective on current best practice and needs for the future management of PsA. Topics of discussion
included the barriers to current best practice and calls to action for the improvement of three areas in PsA management:
early and accurate diagnosis of PsA, management of disease progression and management of the impact of the condi-
tion on the patient. The working group agreed that, to make best use of the available of diagnostic tools, clinical care rec-
ommendations and effective treatments, there is a clear need for healthcare professionals from different disciplines to
collaborate in the management of PsA. By facilitating appropriate and rapid referral, providing high quality information
about PsA and its treatment to patients, and actively involving patients when choosing management plans and setting
treatment goals, management of PsA can be improved. The perspective of the working group is presented here, with
recommendations for the adoption of a multidisciplinary, patient-focused approach to the management of PsA.
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Introduction
Despite the existence of evidence-based screening instruments,
diagnostic tools and treatment recommendations, patients with
psoriatic arthritis (PsA) may not be receiving optimal treat-
ments.1 Whether PsA is diagnosed depends, in part, on whether
a general practitioner (GP) or dermatologist has the specific
knowledge and skill to recognize the symptoms and promptly
refer the patient to a rheumatologist. A delay in treatment of
PsA after diagnosis can result in an increased rate of progression
of clinical damage,2 and quality of life (QoL) can be negatively
affected, with patients experiencing pain,3 fatigue4 and depres-
sion.5 The impact of PsA beyond joint and skin symptoms
strongly indicates that a patient-focused approach should be
emphasized in the management of PsA.6
With this in mind, a multidisciplinary working group com-
prising clinicians, academics and representatives of patient advo-
cacy groups (PAGs) contributed to a virtual summit meeting to
define and agree upon the actions they believe to be helpful to
improve standards of care for patients with PsA in Europe.
Methods
Seven participants were invited from a variety of specialities
(dermatology, rheumatology, behavioural medicine, patient
advocacy) to form a multidisciplinary working group. The
working group convened via a closed online forum (virtual
meeting), with the objective of discussing unmet patient needs
in PsA. A specific body of literature and area of practice was
assigned to each member of the group, who posted to the
forum their professional perspectives and opinions on the
unmet needs and best practice in the treatment of patients
with PsA in Europe. The forum remained open for 4 months
in 2013, during which time the working group was able to
freely discuss the content.
The key topics addressed included the early and accurate diag-
nosis of PsA, the effective management of disease progression,
and how best to reduce the impact of PsA on an individual’s life.
The group also agreed on specific calls to action to improve clin-
ical practice in the patient-focused management of PsA. The
final opinions and perspectives of the group are presented here,
supplemented with information from the literature.
Overcoming barriers to the early and accurate
diagnosis of PsA
Patients with PsA suffer from stiffness, pain, swelling and joint
damage leading to increased disability;7 however, there is not
necessarily an observable pattern or distinctive timing of symp-
toms associated with PsA that is common to all patients. Up to
30% of patients with psoriasis also develop PsA, with skin symp-
toms typically preceding joint problems.2,8 Though no absolute
indicators have been identified to predict that a person with pso-
riasis may develop PsA, the presence of soluble biomarkers, for
example, highly sensitive C-reactive protein (hsCRP), osteopro-
tegerin (OPG), matrix metalloproteinase-3 (MMP-3) and the
C-propeptide of type II collagen to collagen fragment neoepitopes
Col2-3/4long mono ratio or certain susceptibility genes (e.g. cer-
tain human leucocyte antigen alleles [HLA-B and HLA-C]) may
confer susceptibility to PsA among patients with psoriasis.9–12
Moreover, the predictive nature of clinical observations such as
the severity of psoriasis (as measured by the Psoriasis Area
Severity Index [PASI]), the severity of joint involvement and the
presence of certain psoriasis features (e.g. scalp lesions, nail dis-
ease and intergluteal/perianal psoriasis) with respect to the risk
of developing PsA remains unclear.10,13–15 Determining such
absolute indicators for PsA remains complicated because of
varying study designs (e.g. prospective vs. observational studies)
and by potential differences in the clinical observations made by
patients being managed by dermatologists vs. rheumatologists. A
patient with psoriasis who does not report new symptoms con-
sistent with PsA, or a healthcare professional (HCP) who does
not recognize the symptoms of PsA, may inadvertently delay the
diagnosis.
It is difficult to achieve early diagnosis of PsA in the absence
of characterized disease biomarkers or a definitive screening pro-
cedure. Simple and validated screening tests, such as the Psori-
atic Arthritis Screening and Evaluation (PASE) tool, the
Psoriasis Epidemiology Screening Tool (PEST), the Toronto
Psoriatic Arthritis Screen (ToPAS) and the Early ARthritis for
Psoriatic patients (EARP) questionnaire, have been assessed to
determine whether people with suspected PsA should be referred
to confirm the diagnosis (Table 1).16–19 Despite such tools, the
paucity of data from secondary care regarding their feasibility,
sensitivity and specificity, along with the lack of consensus on
which tool is best, hampers their widespread clinical use. In
some cases the sensitivities and specificities of the tools have
been found to be lower than originally reported; when the PASE,
PEST and ToPAS questionnaires were compared in the CON-
TEST study, it was found that they would identify cases of mus-
culoskeletal disease other than PsA, and there was little
difference between the performance of the tools.20
In addition to the use of these tools, rheumatologists need to
share their expertise with dermatologists, to improve under-
standing of the clinical spectrum of PsA among dermatologists
and to facilitate decisions about referral.
For an accurate diagnosis to be made, it is important that
people with suspected PsA are referred to a rheumatologist. Sev-
eral factors can slow the referral process.6 A lack of awareness of
the clinical spectrum of PsA by GPs, compounded by short con-
sultation appointments that prevent a thorough clinical exami-
nation, is a key contributor here. Even if symptoms are
apparent, a GP who lacks specific knowledge about psoriasis and
PsA may not recognize the seriousness of the condition. This
may also be true of dermatologists if they are unfamiliar with
the symptoms of PsA, since a patient is unlikely to be referred to
a rheumatologist unless a specific request is made.
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Inappropriate referral is also a potential issue; while it is likely
that a patient with polyarthritis will be correctly referred, non-
rheumatologists may not be aware that PsA may present with
inflammatory back pain (axial symptoms), enthesitic pain,
tenosynovitis, dactylitis and/or large joint arthritis of the lower
limbs with scarce inflammatory features. Consequently, patients
may initially be referred for an orthopaedic opinion or to a
physiotherapist, rather than a rheumatologist.
Patients may unknowingly present a barrier to their own diag-
nosis. If a person with psoriasis is not aware of the relevance of
joint symptoms, he or she may not report them to a dermatolo-
gist. Equally, a person may attribute symptoms such as pain or
fatigue to causative factors other than PsA. In addition, despite
clinically confirmed joint inflammation and damage, patients
with PsA appear to have higher thresholds for joint tenderness
than patients with rheumatoid arthritis with similar levels of
joint inflammation, further compounding the under-recognition
of their symptoms.21
Delayed diagnosis can have a substantial impact on patients
with PsA. As with any long-term medical condition, early diag-
nosis helps to avoid extended periods of untreated disease,
unnecessary examinations and the use of potentially ineffective
treatment. One study of patients with PsA who fulfilled ClASsifi-
cation of Psoriatic ARthritis (CASPAR) criteria with an average
disease duration of more than 10 years found that even a 6-
month delay from symptom onset to the first visit to a rheuma-
tologist contributed to the development of peripheral joint ero-
sions and worse long-term physical function.22
Recommendations on best practice
To overcome the barriers to early and accurate diagnosis of
PsA, awareness of the condition must be raised and manage-
ment pathways clearly defined. Ideally, dermatologists and
GPs should be familiar with the signs and symptoms of PsA;
at the very least they should be aware that PsA is a common
problem among patients with psoriasis, be able to differentiate
between inflammatory and non-inflammatory joint pain and
be aware of the appropriate referral pathway.23 It is important
to recognize that PsA is a multisystemic disease, to make
HCPs aware of the possibility of the recurrence of PsA among
patients with psoriasis, and to make screening for PsA stan-
dard practice. Early and regular screening, including validated
measures of patient symptoms and with attention to joint
symptoms, would help move towards the ideal situation that
no patient with psoriasis would have their PsA unrecognized
and, if it were to develop during the course of their life, they
would receive appropriate treatment as soon as required. As
soon as PsA is suspected, the patient should be referred to a
rheumatologist for assessment and advice about planning their
care.23,24 In the UK, guidelines issued by the National Institute
for Health and Care Excellence (NICE) recommend that
annual assessments for PsA should be offered to people with
any type of psoriasis.24 Moreover, although NICE considers
assessment to be especially important within the first 10 years
of onset of psoriasis,24 evidence from a cross-sectional study25
and prospective studies26,27 indicate that the risk for develop-
ing PsA remains constant after the initial diagnosis, leading to
a higher prevalence of concomitant PsA with time.
Interaction between rheumatologists and dermatologists can
facilitate the formation of multidisciplinary units for the man-
agement of complex cases. A 4-year study of the implementation
of a multidisciplinary psoriasis and PsA unit improved both the
collaboration between dermatologists and rheumatologists and
the early diagnosis and treatment of PsA.27,28
Patients with psoriasis need to be made aware of the risks of
developing PsA and its long-term consequences through effec-
tive patient education at the time of diagnosis. Patients should
understand that PsA can occur at any time during the course of
psoriasis, there is no known trigger and the presence of PsA does
not involve greater severity of skin psoriasis. Also, patients
should be reassured that although PsA is not a curable disease,
in most cases it is treatable. Patients need to be encouraged to
record and then communicate their skin and joint symptoms to
their HCP. This information can help the HCP make a rapid
Table 1 Screening tools for people with suspected PsA
Tool Users Usage setting Objectives Further notes
Psoriatic Arthritis Screening
and Evaluation (PASE)16
Dermatologists Secondary care  For assessment of likely joint symptoms
in patients with psoriasis, and directing
referral to rheumatologist
 Assessment of the impact of symptoms
on the patient, in terms of disability
 Can distinguish between PsA
subtypes
 Can distinguish between PsA
and osteoarthritis
Psoriasis Epidemiology
Screening Tool (PEST)18
GPs, hospital clinicians Community setting
and hospital clinic
 Detection of PsA in patients with
existing psoriasis
 Uses a diagram or a
mannequin to allow patients
to identify location of
symptoms
Toronto Psoriatic Arthritis
Screen (ToPAS)17
GPs, dermatologists,
rheumatologists
Primary and
secondary care
 Identiﬁcation of PsA in patients with
existing psoriasis or in general population
 Uses images of skin/nail
involvement for screening
Early ARthritis for Psoriatic
patients (EARP)19
Dermatologists,
rheumatologists
Secondary care  Early identiﬁcation of PsA in patients
with existing psoriasis
 Simpler and faster than PASE
© 2015 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology.
JEADV 2015, 30, 576–585
578 Betteridge et al.
and appropriate referral, helping to ensure a timely and accurate
diagnosis by the rheumatologist.
At the first consultation with the rheumatologist, during
which the diagnosis is established, disease information is essen-
tial. Small amounts of relevant information given over time, in
combination with goal setting and action planning, will help the
patient to accept the diagnosis, maintain motivation to self-
manage and remain adherent to management plans. Patient
engagement and activation at the outset are essential and a self-
management programme based on psychological principles that
includes addressing patients’ beliefs will be more beneficial than
supplying information and relying on the patient to digest,
remember and understand it.29 The patient should be empow-
ered to request information about any points that they do not
understand about their disease or treatment, standards of care,
pathways for referral and collaboration between specialists of
different disciplines. By engaging with patients with suspected
PsA, PAGs can assist by providing relevant and targeted infor-
mation about the signs and symptoms of PsA and when to alert
the dermatologist.
Calls to action: improving early and accurate diagnosis
1 Health authorities and academic societies should create edu-
cational awareness campaigns aimed at GPs and dermatolo-
gists about the symptoms of PsA to improve understanding
of the disease.
2 HCPs should regularly screen psoriasis patients for signs and
symptoms of PsA.
3 GPs, dermatologists and rheumatologists should coordinate
their efforts to ensure patients are referred in an appropriate
and timely fashion, and that treatment of the patient is not
restricted to only the skin and joints.
4 Rheumatologists should implement head-to-head studies of
the screening tools for PsA to help define their usage and
application and drive their refinement.
5 PAGs should support and help to run educational pro-
grammes to help patients recognize symptoms of PsA and
actively seek referral to a rheumatologist.
6 Soon after diagnosis, HCPs and PAGs should provide infor-
mation to patients with PsA to help inform their understand-
ing of the natural course of disease, including long-term joint
damage, as well as the benefits of available treatments.
7 Patients should be offered support from suitably qualified
personnel to assist with self-management and address distress
resulting from PsA.
Addressing the challenges to the effective
management of PsA disease progression
A survey of more than 5000 patients with psoriasis and
PsA, conducted by the National Psoriasis Foundation in the
US between 2003 and 2011, revealed that 46% of those with
PsA are dissatisfied with their treatment.30 This suggests that
new options and approaches to PsA management are neces-
sary.30
The main challenges to effective long-term management of
PsA are the control of structural damage to bone and cartilage
and the preservation or enhancement of QoL. Structural dam-
age, both axial and peripheral, is the variable that best correlates
with long-term disability.31 However, tools designed to specifi-
cally assess structural damage are currently lacking and most
have been adapted from other rheumatic musculoskeletal dis-
eases.
In recent years, the availability of highly effective treatments
such as biological therapies has led to the use of treat-to-target
strategies.32 While recommendations for such an approach
with rheumatoid arthritis have been developed,33 adopting a
treat-to-target strategy for PsA presents a greater challenge for
a number of reasons:34 the heterogeneous presentation of PsA,
the scarcity of data to support the treatment of PsA to a tar-
get, and a lack of definitions of the specific criteria for remis-
sion of PsA.32 The TIght Control of Psoriatic Arthritis
(TICOPA) trial has shown that a treat-to-target approach in
patients with newly diagnosed PsA can significantly improve
joint outcomes. Patients randomized to tight control (using
methotrexate, combination disease-modifying antirheumatic
drugs [DMARDs] and antitumour necrosis factor drugs) had
a greater chance of achieving an American College of Rheuma-
tology (ACR) 20 response at 48 weeks than patients treated
with standard care. Although more adverse events were seen
in the tight control group, no unexpected serious adverse
events were seen.35 While adherence to a treat-to-target strat-
egy may improve outcomes, the specifics and feasibility of
employing such a protocol in widespread clinical practice
requires further investigation.
Even when the most appropriate management plan is initi-
ated, a person with PsA might not adhere to it. Patients may
hold unhelpful or erroneous beliefs about the cause, conse-
quences, control and timeline of the condition and/or the medi-
cal interventions prescribed. Anxiety and depression, conditions
associated with PsA,36 can lead to low adherence in chronic dis-
ease,37 and a low sense of confidence or ability of the patient to
self-manage. Overly complex medication regimens may also
impair adherence,38 particularly if the patient does not under-
stand the need for each component or is concerned about
unwanted effects.
While a multidisciplinary approach might be the most attrac-
tive option for the care of patients with PsA, imbalances between
the numbers of rheumatologists and dermatologists may result
in difficulties when trying to develop pan-European recommen-
dations for referral and management.6 For instance, in a country
with relatively few rheumatologists, they are likely to share their
time between patients with a range of inflammatory muscu-
loskeletal diseases, and may not be able to dedicate a large
amount of it to PsA patients.
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Finally, there are financial and political barriers to effective
PsA management. Patients with PsA incur substantial direct and
indirect costs of illness, and are significant users of healthcare
resources through regular visits to GPs and specialists, and also
hospitalization.39 The Norwegian DMARD register indicates
that, for treatment of PsA, 6-month direct costs (including drug
costs and patient care) for synthetic and biological DMARDs
can reach €1795 and €11 317, respectively, although these costs
can decline as treatment proceeds.40 Indirect costs (mainly pro-
ductivity losses) for a 6-month period can reach €15 552 and
€20 762 for synthetic and biological DMARDs, respectively.40
Because psoriasis and PsA are long-term conditions, consistent
and repeated costs can accumulate quickly. If a country’s health
authority does not recognize psoriasis and PsA as lifelong debili-
tating conditions, or offer appropriate reimbursement, then the
patient’s access to treatment may be limited.
Recommendations on best practice
Multiple evidence-based recommendations for the diagnosis and
treatment of PsA have been developed for use throughout Eur-
ope, including European-level statements, national guidelines
and recommendations (Table 2). For example, the recommen-
dations for best practice in the treatment of PsA developed by
GRAPPA are a survey of the best available evidence and the con-
sensus of an international group of rheumatologists and derma-
tologists.41 Their recommendations differentiate between the
treatment of peripheral and axial arthritis, enthesitis, skin and
nails, and dactylitis. Advice is also given on grading disease
severity to aid decision-making. EULAR (the European League
Against Rheumatism) has also established and published recom-
mendations for the management of PsA, which are based on best
available evidence and current expert opinion, including that of
patients.42
Although guidelines and recommendations are crucial to
inform good practice, the needs of the patient should always be
at the forefront of clinical decisions. Following prompt referral
and diagnosis, it is important to explain the characteristics of the
disease. A clear and simple management plan should be decided
upon with the patient using shared decision-making tools and
techniques, individualized according to their symptoms and pre-
dominant pattern of disease, defining treatment goals, initiation,
adaptation and follow-up. Patients’ preferences and expectations
should be considered, and their current level of knowledge on
the condition and what they want from services and specialists
should be established. Improving a patient’s knowledge of the
disease and the treatment available can improve treatment
adherence.43 With the objective of maximizing adherence, con-
sultations should include information on mood, lifestyle, level of
disability and therapeutic goals. The long-term effects of PsA
and other future issues should be discussed, and patients should
be informed about any national or regional PAGs that can offer
further information and support. Positive steps should be taken
to address a patient’s beliefs about PsA and the associated treat-
ment, as these can have a bearing on adherence to a manage-
ment plan.
Patient evaluations should be repeated depending on disease
severity and response to treatment, but during the first 2 years
they should be performed every 2–6 months to assess treatment
response. Depending on the outcome of these assessments, treat-
ment modification might be considered according to the
achievement or failure to achieve the planned therapeutic objec-
tives. Patients should be encouraged to take an active role,
through self-assessment and reporting back to the rheumatolo-
gist at regular appointments. The variables to be assessed should
be relevant to the disease pattern of PsA and should also include
the evaluation of skin disease and the detection of possible
co-morbidities (such as metabolic syndrome, cardiovascular dis-
ease or impaired liver function); lifestyle and personal factors
(such as mood, smoking and alcohol intake) may also influence
the choice of therapy. Medications used to control existing
Table 2 Evidence- and consensus-based recommendations for diagnosis and management of PsA
Region/country Group/society involved in the development of the recommendations Year of issue Audience
International Group for Research and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA)41
2009 All clinicians caring for patients with PsA
International The Psoriatic Arthritis Forum60 2014 Rheumatologists
European European League Against Rheumatism (EULAR)42 2012 Those affected by PsA or those involved
in the management of PsA
European Working group of dermatologists and a rheumatologist59 2014 Rheumatologists and dermatologists
French French Society for Rheumatology61 2007 Rheumatologists
Italy Italian Society for Rheumatology62 2011 Rheumatologists
Portugal Portuguese Society of Rheumatology63 2012 Rheumatologists
Spain Spanish Society of Rheumatology64 2011 Rheumatologists
UK British Society of Rheumatology65 2012 Rheumatologists and prescribing clinicians
National Institute for Health and Care Excellence24 2012 All clinicians caring for patients with
psoriasis and/or PsA
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co-morbidities may need to be considered when choosing a
treatment plan. Regular examination and re-evaluation of the
management plan should help patients with PsA to achieve the
best outcomes. A series of key questions to pose to people with
suspected PsA, or in whom PsA has been diagnosed but progres-
sion needs to be followed, has been published previously by
Radtke et al.44
In the Swedish Early Psoriatic Arthritis Register, a study with
5-year follow-up, recognition of PsA soon after the onset of
symptoms was one of the important predictors of favourable
clinical outcomes; prompt active treatment was also considered
important.45 Furthermore, early diagnosis and treatment of PsA
with a DMARD may reduce joint damage compared with later
initiation of treatment;22 better outcomes have been associated
with initiation of therapy within 2 years of onset of PsA, com-
pared with 2 years after onset.46
As treatment with a DMARD can lead to the improvement of
QoL,47 the positive effects of early treatment may extend beyond
the clinical outcomes.
Increasing patients’ understanding of PsA is important, but
can be challenging, and requires the active involvement of a
number of parties (Table 3). One such party are PAGs, which
play an important role at both the national and European level
to enhance the availability of care. For example, the Brussels
Declaration, a document developed by EULAR, summarizes the
needs, wishes and declared rights of people living with all forms
of rheumatic and musculoskeletal diseases (including PsA).48
Since its presentation at a meeting of health ministers from every
country in the EU in October 2010, many Members of the Euro-
pean Parliament have signed up to support the statement. Pre-
sentation of the Brussels Declaration in Bulgaria and Serbia has
led to enhancements in healthcare for patients with rheumatic
disease, including improvement in access to biological treat-
ments. Collaborative campaigning by pan-European research
groups, academic institutions and several PAGs has contributed
to rheumatic diseases being given a priority status in the subse-
quent EU Research Framework programme, Horizon 2020. As a
result, rheumatic disease is currently named alongside cancer
and diabetes as a major condition in terms of research.
Consensus among experts is that PsA demands a collaborative
approach between rheumatologists and dermatologists since the
majority of people with PsA have existing psoriasis. The nature
of such a collaboration will naturally depend on national health-
care systems. Clinical decision-making must take into account
all domains of the disease and the patient should be an active
member in developing their treatment plan.41,42
Calls to action: improving the effective management of
PsA
1 HCPs should be aware of and implement evidence-based
guidelines and recommendations for the diagnosis and man-
agement of PsA to optimize treatment of their patients as
early as possible in the course of disease.
2 Academic societies that have developed evidence-based
guidelines and recommendations should review and update
them on a regular basis, consulting patients and/or PAGs to
ensure an emphasis on patient-focused care.
3 HCPs should work together to design, develop and validate
new tools specifically designed to assess PsA in terms of joint
damage.
4 Industry and HCPs should continue to undertake clinical
research and initiate PsA registries to determine the long-
term risks and benefits of drugs currently used for the treat-
ment of PsA, to define treatment targets for PsA and to evalu-
ate the risks and benefits of intensive treat-to-target therapy
in comparison to current standards of care.
5 Dermatologists, rheumatologists, psychologists, specialist
nurses and PAGs should collaborate to adopt an individual-
ized, multidisciplinary approach to the care of patients with
PsA.
Table 3 Increasing disease awareness amongst patients
Inﬂuencer Role in increasing patient awareness Barriers to increasing patient awareness
Dermatologist/GP To inform patients about the characteristics and
consequences of their disease in a timely and
appropriate way, before referral to the rheumatologist
 Lack of HCP disease education (signs and symptoms,
disease burden, referral process, etc.)
 Lack of early detection campaigns
 Lack of multidisciplinary units for the management of
PsA
Specialist nurse To assist specialists, promote communication within
the multidisciplinary team and help patients
understand their treatment regimens including
administration, medication type, monitoring
requirements, side effects, misuse, etc
 Do not exist/are not deployed in all countries
 Appropriate training required
Medical societies To serve as an up-to-date resource for information
about PsA
 Lack of patient awareness that medical societies are a
source of information
PAGs To provide information covering practical issues
(e.g. lifestyle and diet) from the perspective of the
patient
 Requires multidisciplinary collaboration between
PAGs, rheumatologists and dermatologists
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a. To inform and drive the establishment of multidisci-
plinary teams, clinics and hospitals in which a successful
collaboration has been forged should share best practice
on how this was achieved and maintained, and the out-
comes for patients.
b. HCPs and PAGs should collaborate to develop and dis-
tribute high quality information to patients with PsA,
enabling them to clearly understand and communicate
their current disease status.
6 Patients should be encouraged and empowered to take an
active role in setting individualized, achievable therapeutic
goals and choosing an appropriate management plan, with
access to a range of treatments.
Mitigating the impact of PsA on the patient
In comparison with the general population, patients with PsA
have higher co-morbidity scores, with the most prevalent co-
morbidities reported being hypertension, heart diseases, chronic
respiratory diseases and gastrointestinal conditions.49 An ele-
vated risk of cardiovascular disease is also known to occur in
psoriasis,50 and is responsible for 20–56% of deaths in patients
with PsA.51 Alongside high disease activity, the presence of co-
morbidity has been found to impact health-related QoL
(HRQoL) in patients with PsA.49 Moreover, patients with PsA
can have a significantly lower HRQoL than the general popula-
tion.39,49
As assessed by the Short Form 36-item Health Survey Ques-
tionnaire (SF-36), a widely used example of a generic health pro-
file, significant impairments have been observed across all eight
of the domains of HRQoL, including physical and social func-
tioning and mental health, in patients with inflammatory rheu-
matic disease, including PsA, indicating that it is sensitive for
use in the PsA population.49 In addition to the impact found on
physical functioning, poor mental functioning was associated
with the severity of psoriatic lesions.49
Studies assessing patients’ opinions about their health condi-
tion, which reflect the patient burden of disease, are limited in
PsA. Published trials assessing patient-reported outcome mea-
sures (PROMs) have largely focused on a core set of domains
including pain, patient global assessment, physical function and
HRQoL using either generic tools or those that have been
adapted from rheumatoid arthritis. As such, other dimensions of
health may be important in PsA. With the support of EULAR
the PsA Impact of Disease (PsAID) questionnaire, a focused tool
for assessing PROMs in patients with PsA, has recently been
developed and validated.4
Two questionnaires were developed, one for clinical trials
and one for clinical practice. Of 16 domains of health, pain,
fatigue and skin problems had the highest relative importance
as identified by 139 patients with PsA (Fig. 1). Pain of vary-
ing degree is a common occurrence in all types of arthritis.
In a survey conducted by the UK charity Arthritis Care of
2263 people with all types of arthritis (8% of whom had a
diagnosis of PsA), 35% experienced some form of pain (mild
to severe pain) and 32% of respondents said that their every-
day pain was often unbearable and frequently stopped them
from doing daily activities.3
Fatigue, which was identified by the PsAID questionnaire as
important in patients with PsA,4 is commonly experienced in
patients with PsA. In a Canadian study, half of all patients with
PsA reported moderate fatigue and 29% reported severe fati-
gue.52 A combination of pain, fatigue and anxiety can result in a
vicious cycle, worsening the symptoms and impact of PsA and
psoriasis. Patients may report reduced activity, resulting in poor
physical fitness due to a combination of joint pain and fatigue.
Lack of sleep and unwanted effects of medication may cause irri-
tability, and with low energy levels patients may withdraw from
favoured activities. A cross-sectional study that included 83
patients with PsA showed an incidence of moderate to severe
levels of depressive symptoms in 22% of the cohort.5 Anxiety
and concern about bodily symptoms were also seen to affect
HRQoL.5 Taken together, these factors will negatively influence
interpersonal and family relationships, and can contribute to
work absenteeism and hence affect career prospects; however,
further high quality research is needed to determine the extent
of this effect.
Not only does PsA affect a patient’s QoL, but it can also have
an economic impact on society.39 In addition to the direct costs
of PsA management, lost productivity can result from increased
disability and the significantly lower employment of patients
with PsA, compared with the general population.39,53 Close to
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Figure 1 Sixteen domains of health were identiﬁed as important
by 12 patients with PsA; the proportion of 139 patients considering
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ing to median order of importance (range of importance 1–16).
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one-third of patients with PsA may also make short-term or per-
manent disability claims, costs for which increase substantially
with duration of disease.39
Recommendations on best practice
Assuming PsA is correctly diagnosed and effectively managed,
the first step in helping to reduce the impact on the patient must
be to fully understand how the disease affects them. For instance,
in the UK, NICE guidelines recommend that people with any
type of psoriasis (which should extend to PsA) should be
assessed for the impact of disease on physical, psychological and
social well-being to formulate an appropriate intervention.24
More and better quality studies are required to determine the
nature of the association between severity of symptoms and psy-
chological impact.
Despite being an important objective in the long-term treat-
ment of PsA, QoL continues to be a variable that is seldom con-
sidered for therapeutic aims. Although the generic SF-36
questionnaire, reflective of overall QoL, can be applied, a specific
QoL measure that encompasses both skin and articular disease
would be preferred, since they each contribute in an additive
manner to the disability and worsening of mood in patients. The
development and validation of new tools, centred on HRQoL
and patient-reported outcomes, such as those identified in the
VITACORA and PsAID questionnaires,4,54 should help
strengthen data from clinical trials and aid clinical management
in terms of the impact of the disease on the patient.
For the results to be used effectively, QoL measures should be
deployed correctly. The SF-36 questionnaire may be adminis-
tered effectively by an interviewer with appropriate training, and
the PsAID questionnaire, which deals with psychological aspects
of disease burden, is an easy self-reported questionnaire.54 Der-
matologists and rheumatologists should not assume that nursing
staff do or can provide this support without training. Therefore,
an assessment of psychological functioning should be considered
as part of the full assessment, although this is not realistic in all
cases. When assessing a patient with PsA, a psychologist may
choose to forfeit a QoL measure in favour of a more specific ill-
ness beliefs and distress measure, as these tools help to better
formulate an intervention. The Brief Illness Perception Ques-
tionnaire (BIPQ) and the Hospital Anxiety and Depression Scale
(HADS) are both appropriate for this purpose. When beliefs are
targeted and patients assisted in setting meaningful disease man-
agement goals, it is likely that QoL will be improved.
Although not trialled in PsA specifically, cognitive beha-
vioural therapy has shown efficacy in improving psychological
functioning in other long-term conditions, including psoria-
sis.55,56 Such an intervention aims to address beliefs, help mood
management and improve QoL, but further research is required
to determine the acceptability of this approach and its applica-
bility in PsA specifically.57
Calls to action: easing the impact of PsA for the patient
1 PsA needs to be universally recognized as a multifactorial,
long-term and debilitating condition that can cause signifi-
cant physical and psychological impairment and reduction in
QoL.
2 Clinical trials of drugs for the treatment of PsA should collect
patient-reported outcomes and QoL data, to supplement effi-
cacy and safety data.
3 An integrated psychological approach to clinical management
should be adopted for patients with PsA.
4 Patients should be referred for psychological assessments
when needed; e.g. at diagnosis, when the disease progresses
or when treatment changes.
5 PAGs should continue to actively participate in meetings of
groups that develop guidelines and recommendations, to
provide the patient perspective of the psychosocial burden of
PsA and to outline the support required.
6 PAGs should engage with governments and health authorities
to raise awareness of the burden associated with PsA and
ensure that its burden is addressed in future policies.
Conclusions and future perspectives
Despite the availability of diagnostic tools, effective treatments
and supportive infrastructure, patients with PsA are still not
receiving the optimal level of care. This review has presented a
series of considerations for improvement of the level of care for
patients with PsA.
There are many ways in which to improve patient outcomes
in PsA, but the requirement for the involvement of more than
one healthcare discipline can complicate planning and execu-
tion. If dermatologists and rheumatologists agree a process for
collaboration, ask patients the right questions and ensure that
patients are fully engaged, time to diagnosis could be signifi-
cantly reduced and appropriate treatment delivered sooner. A
previous initiative that presented strategies for the improvement
of care for people with psoriasis, the European Psoriasis White
Paper, took a similar approach to that described here to engage
with the multiple stakeholders who have responsibility for
improving patient care.58
While cooperation between dermatologists and rheumatolo-
gists has been proposed before,59 a fully integrated and collabo-
rative approach between dermatologists, rheumatologists,
specialist nurses, psychologists, patients and PAGs would build
understanding of PsA and its impact on the patient and optimize
its management.
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